Semaglutide for Weight Loss: How Treatment Works, Results, Side Effects & Eligibility

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist: a prescription medication that mimics glucagon-like peptide-1, which is a hormone that your body produces naturally after eating. It was first developed for type 2 diabetes management and later studied extensively for chronic weight management, where it demonstrated weight loss results that have changed how clinicians think about obesity treatment.

Semaglutide is available in several FDA-approved products with different formulations and indications. Wegovy is available as both an injection and an oral tablet for weight management in eligible patients; Ozempic and Rybelsus are semaglutide products used for type 2 diabetes and other labeled indications. These products have different doses, formulations, and prescribing instructions and should not be treated as interchangeable.

Lttl offers compounded semaglutide for weight management. Compounded semaglutide is not FDA-approved and has not been independently evaluated by the FDA for safety, efficacy, or quality. Lttl works exclusively with state-licensed 503A compounding pharmacies that source active pharmaceutical ingredients from FDA-registered manufacturers, and every order ships with a Certificate of Analysis verifying purity and potency.

How Does Semaglutide Support Weight Loss?

Semaglutide works by activating GLP-1 receptors throughout the body and brain: the same receptors engaged by the GLP-1 hormone your body produces naturally after a meal. The difference is duration: natural GLP-1 breaks down within minutes, while semaglutide is engineered to last approximately one week, maintaining a sustained effect on the systems it targets.

Here's how that works:

Appetite quiets. GLP-1 receptors in the brain (particularly in regions involved in hunger, reward, and decision-making) receive a sustained signal that reduces the mental preoccupation with food many patients describe as "food noise." Meals feel satisfying with less food. The pull toward habitual or compulsive eating weakens.

Digestion slows. Semaglutide activates GLP-1 receptors in the stomach, slowing gastric emptying (the rate at which food moves into the small intestine). So, your food sits longer, and your fullness extends further between meals.

Blood sugar stabilizes. Semaglutide stimulates insulin release in a glucose-dependent way and suppresses glucagon, reducing blood sugar spikes after meals. More stable blood sugar means fewer energy crashes and fewer of the hunger signals those crashes trigger.

Caloric intake decreases. These effects compound each other, producing a meaningful and sustained reduction in how much most patients eat, without the constant effort of willpower-driven caloric restriction.

For a deeper look at the science, see our full guide to how GLP-1 medications work.

Who May Be Eligible for Semaglutide Treatment?

Semaglutide for weight management requires a prescription, and eligibility is determined through clinical evaluation: not a checklist or a self-assessment. That said, a few general factors commonly inform whether a patient may be a candidate.

• BMI. FDA-approved Wegovy and compounded semaglutide programs generally follow the same clinical criteria: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
• Weight-related comorbidities. Conditions like hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease can support eligibility at lower BMI thresholds.
• Medical history. Certain conditions are contraindications. A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) means semaglutide should not be used. History of pancreatitis, significant gallbladder disease, or severe gastroparesis all require careful evaluation.
• Current medications. Patients taking insulin or sulfonylureas need clinical guidance on dose adjustments to reduce hypoglycemia risk. Patients on oral medications with narrow therapeutic windows should have absorption timing reviewed, since semaglutide slows gastric emptying and can affect how other drugs are absorbed.
• Pregnancy or plans to conceive. Semaglutide should not be used for weight reduction during pregnancy because it may cause fetal harm. Wegovy should be discontinued when pregnancy is recognized and stopped at least two months before a planned pregnancy. Breastfeeding recommendations differ by formulation; breastfeeding is not recommended during treatment with Wegovy tablets.
• Age. Wegovy is approved for adults and adolescents aged 12 and older. Lttl's programs are for adults.

Eligibility is ultimately a clinical determination made by a licensed clinician who reviews your complete health history. Lttl's intake process makes that a quick and easy process. Our questionnaire takes just two minutes to complete and goes straight to a licensed clinician for review.

What Results Can You Expect With Semaglutide?

The evidence base for semaglutide weight loss is among the strongest in modern obesity medicine. In the STEP 1 trial (one of the largest weight loss studies conducted for any medication), adults with obesity or overweight without diabetes lost an average of approximately 15% of their body weight over 68 weeks on semaglutide 2.4 mg weekly. Adults with type 2 diabetes in STEP 2 lost an average of approximately 9.6% over the same period. The SELECT cardiovascular outcomes trial, which ran approximately 40 months, showed continued benefit in a high-risk population.

These are averages, of course, and individual results can range widely above and below them. Several factors can influence response: dose reached and maintained, adherence, baseline health, protein intake, physical activity, sleep quality, and whether other medical conditions or medications are affecting metabolism.

The timeline matters, too. The early weeks of your program are primarily about adjustment (appetite changes, GI adaptation, and dose titration) rather than dramatic scale movement. Most patients begin to see consistent fat loss around months two and three, with results continuing to build as the protocol progresses. Semaglutide clinical trials ran 68 weeks for a reason: that's how long it takes for the full effect to develop.

Lifestyle factors remain relevant throughout, though. Semaglutide creates favorable conditions (reduced appetite, more stable blood sugar, quieter food-related thoughts), but patients who use that window to build sustainable habits around nutrition and physical activity tend to do better over time than those who rely on the medication alone.

How Semaglutide Treatment Works With Lttl

Starting semaglutide through Lttl follows a clear, clinician-led process from intake to ongoing care.

1. Complete the free health assessment. The process begins with a comprehensive health questionnaire covering your medical history, current medications and supplements, relevant family history, and your treatment goals. This takes about two minutes and is the foundation of everything that follows. The answers directly affect what your clinician prescribes, at what dose, and whether semaglutide is appropriate for you at all.

2. Clinician review. A licensed clinician reviews your intake individually: not an algorithm or a decision tree, but a real clinician evaluating your case. They assess whether semaglutide is medically appropriate for your specific situation, identify any factors that require additional caution, and determine your starting dose and titration plan. Treatment may be declined if it isn't clinically appropriate.

3. Lab work, if needed. Depending on your health history, your clinician may request recent lab results (metabolic panel, thyroid function, or other relevant markers) before finalizing your treatment plan. If you have recent results from your primary care provider, those can often be submitted directly.

4. Prescription and pharmacy fulfillment. When treatment is prescribed, your compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy sourcing active pharmaceutical ingredients from FDA-registered manufacturers. Your medication ships discreetly to your door, typically within one week of prescription approval, with a Certificate of Analysis verifying purity and potency.

5. Ongoing monitoring and care. Dose titration, side effect management, and clinical check-ins are part of responsible semaglutide care, not optional extras. Lttl's membership includes unlimited access to our care team for questions about side effects, missed doses, dose adjustments, or anything else that comes up. Your price doesn't change when your dose does.

Semaglutide Dosing and Titration

Semaglutide dosing for weight management is not one-size-fits-all. The standard approach starts at a low dose and increases gradually over time (a process called titration) to give the body time to adapt at each level before moving higher.

For Wegovy (the FDA-approved weight management formulation), the standard escalation moves through 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose over approximately 16 weeks. Some patients tolerate this schedule well; others benefit from a slower escalation. The prescribing label allows for delays in dose escalation when tolerability is an issue.

Compounded semaglutide programs, including Lttl's, follow individualized titration plans developed by your clinician based on your health history and how you're responding to treatment. The active ingredient is the same, but the specific dosing schedule and formulation details can differ from branded products. This is one reason clinical oversight throughout treatment matters as much as the initial prescription.

A few principles worth understanding:

• Higher doses are generally associated with greater weight loss, but not every patient needs or can tolerate the maximum dose.
• The goal of titration is to find the dose that balances efficacy and tolerability for you specifically: not to reach the highest available dose as quickly as possible.
• Do not adjust your dose independently based on side effects or perceived results. Dose changes should be made with your clinician's guidance.

Semaglutide Side Effects and Safety

Most people who start semaglutide experience some side effects, particularly in the early weeks. The majority are gastrointestinal and manageable, but some symptoms require prompt medical attention.

Common Side Effects	Serious Symptoms - Seek Prompt Care
Nausea (~44% in STEP trials)	Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis)
Diarrhea (~30%)	Upper right abdominal pain, fever, or jaundice (possible gallbladder disease)
Vomiting (~24%)	Signs of a serious allergic reaction: swelling of face, lips, tongue or throat; difficulty breathing
Constipation (~24%)	Rapid or irregular heartbeat at rest
Abdominal pain (~20%)	Vision changes in patients with type 2 diabetes
Headache (~14%)	Persistent vomiting with inability to keep fluids down
Fatigue (~11%)	Neck lump, hoarseness, or difficulty swallowing (possible thyroid tumor)
Hair loss (~3%)	Any symptom that feels severe or unusual

Wegovy carries a boxed warning for a potential risk of thyroid C-cell tumors based on animal studies. Human relevance has not been established, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.

The suicidal behavior and ideation warning that previously appeared in Wegovy's prescribing label was removed in January 2026 following an FDA review that did not establish a causal link.

Practical management for common side effects: eat smaller meals more slowly, avoid high-fat or heavily spiced food early in treatment, stay upright after eating, prioritize hydration, and maintain adequate protein and electrolyte intake.

For a complete guide to managing side effects and understanding the full safety profile, see our dedicated semaglutide side effects article.

How Much Does Semaglutide Treatment Cost?

The cost of semaglutide treatment depends on several variables: whether you're accessing brand-name or compounded medication, your insurance coverage, the pharmacy dispensing your medication, your dose, and what your telehealth provider includes in their pricing.

Brand-name Wegovy lists at approximately $1,350 per month without insurance. Insurance coverage for weight management indications is inconsistent: many employer-sponsored plans exclude it, and prior authorization is commonly required even when coverage exists in principle.

Lttl's compounded semaglutide is currently available at $89 per month, all-inclusive. That price covers your medication, clinician oversight, unlimited care team access, dose adjustments, and shipping. There are no required add-ons, separate consultation fees, or surprise charges when your dose changes.

Compounded semaglutide is not FDA-approved and has not been independently evaluated by the FDA for safety, efficacy, or quality. For a full breakdown of how GLP-1 medication costs vary and what to look for before choosing a provider, see our GLP-1 cost and access guide.

Semaglutide vs Other GLP-1 Treatment Options

Semaglutide is one of two GLP-1 medications most commonly used for weight management. The other is tirzepatide, which activates both GLP-1 and GIP receptors, a dual mechanism that produces more pronounced appetite suppression in many patients and greater average weight loss in clinical trials.

A few points worth knowing when comparing the two:

• Mechanism. Semaglutide activates GLP-1 receptors only. Tirzepatide activates GLP-1 and GIP receptors simultaneously, engaging an additional hormonal pathway involved in metabolism and energy regulation.
• Clinical trial averages. Semaglutide produced approximately 15% average weight loss in STEP 1 (adults without diabetes, 68 weeks). Tirzepatide produced approximately 22.5% in SURMOUNT-1 (similar population, 72 weeks). Remember, these are averages and individual results can vary considerably for both.
• Titration pace. Semaglutide's standard escalation is slower than tirzepatide's, which some patients find easier to tolerate early in treatment.
• Track record. Semaglutide has a longer published clinical history and more long-term safety data.
• Right fit. Neither medication is universally better. The right choice depends on your health history, treatment goals, tolerability, and your clinician's assessment.

For a detailed side-by-side comparison, see our semaglutide vs. tirzepatide guide.

Frequently Asked Questions About Semaglutide

How Long Does It Take for Semaglutide to Work?

Appetite changes (quieter food noise, earlier satiety, reduced cravings) often appear within the first one to two weeks. Measurable fat loss typically becomes consistent around months two and three as the titration progresses and a sustained caloric deficit develops. The STEP trials ran 68 weeks to capture the full trajectory of treatment. The first month is an adjustment period, not a representative sample of what semaglutide can do.

How Long Do You Have to Take Semaglutide?

GLP-1 therapy is generally framed as a long-term treatment rather than a short course. The STEP 4 withdrawal trial showed significant weight regain after discontinuation. Patients who stopped semaglutide regained a meaningful portion of their lost weight over the following months, while those who continued treatment kept losing. This doesn't mean treatment is indefinite for everyone, but it does mean that planning for ongoing use tends to produce more realistic expectations than treating it as a temporary fix.

Can I Switch From Semaglutide to Tirzepatide?

Yes. Some patients switch because they've plateaued on semaglutide, aren't tolerating it well, or their clinician recommends it based on their progress. Transitions between medications should be managed clinically (including decisions about timing and starting dose) rather than made independently. If you're considering a switch, raise the topic with your Lttl care team rather than making the change on your own.

What Happens if Semaglutide Isn't Working for Me?

If you're not seeing meaningful progress after reaching a stable maintenance dose for an appropriate period, the right step is clinical reassessment rather than independent dose escalation. Your clinician can review adherence, dietary intake, activity, dose tolerability, and whether underlying factors (such as other medications, medical conditions, or sleep quality) may be affecting your response. Semaglutide doesn't work identically for everyone, and a clinician review often identifies something actionable.

Is Semaglutide Available Through Telehealth?

Yes. Telehealth has made GLP-1 therapy significantly more accessible for patients who don't have a local obesity medicine specialist or whose schedule makes repeated office visits difficult. The key is finding a telehealth provider offering a licensed clinician who actually reviews your case individually rather than processing prescriptions automatically. Lttl's model is built around genuine clinician evaluation: no prescription is written until a licensed clinician has reviewed your health history and determined that treatment is appropriate. Our care team is available throughout your program, not just at the start.

What Is the Difference Between Compounded and Brand-Name Semaglutide?

Brand-name Wegovy is FDA-approved after clinical trials evaluating its safety, efficacy, and quality. Compounded semaglutide is prepared by licensed pharmacies using the same active pharmaceutical ingredient, but is not FDA-approved and has not been independently evaluated by the FDA. The quality of compounded semaglutide depends on the pharmacy producing it and the clinical oversight of the prescribing provider. Lttl uses state-licensed 503A compounding pharmacies sourcing APIs from FDA-registered manufacturers, with Certificates of Analysis provided for every order. For a full explanation of the regulatory differences, see our compounded vs. FDA-approved GLP-1 medications guide.

Bibliography

• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
• Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Full prescribing information (Revised March 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
• Drucker, D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://pubmed.ncbi.nlm.nih.gov/34626851/
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038